N/A N=48 Attention Disengagement Training for Social Phobia
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 68.1; 74.5; 60.0; 46.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
Phase 3 N=61 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 7.77; 7.84 units on a scale — p=.267
Phase 4 N=181 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
Social Phobia
Primary: Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders — 17; 11; 10 participants
N/A N=250 1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety
Social Anxiety
Primary: Liebowitz Social Anxiety Scale — 81.05; 82.74; 64.11; 73.05 score on a scale
Phase 3 N=511 Experimental Medication For the Treatment of Generalized Anxiety Disorder
Anxiety Disorder
Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
N/A N=76 A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status
Phase 3 N=27 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
Generalized Social Phobia
Primary: Clinical Global Impression (Change Version, Also Known as Improvement Version) — 3; 4 participants
Phase 2 N=83 SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Generalized Anxiety Disorder (GAD) · Anxiety, Separation · Phobia, Social
Primary: Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks — -1.7; -2.3 mmHg
Phase 2 N=69 Combined Treatment for Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Hamilton Anxiety Rating Scale (HAM-A) — 25.9; 23.8; 20.9; 19.4 units on a scale — p=.17
N/A N=49 Interpretation Modification Program for Social Phobia
Social Anxiety Disorder · Social Phobia
Primary: Liebowitz Social Anxiety Scale (LSAS) — 82.0; 77.7; 50.2; 67.6 units on a scale
Phase 3 N=495 EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder (GAD)
Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale
Phase 2 N=151 A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 22.42; 24.26…
Phase 3 N=210 Duloxetine for the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006
Phase 3 N=409 Generalized Anxiety Disorder Adjunct Study
Anxiety · Anxiety Disorders · Anxiety Neuroses
Primary: Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.74; -9.61 units on scale
Phase 4 N=63 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score — 93.4; 92.1; 55.0; 63.4 Scores on a scale
Phase 4 N=25 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…
N/A N=30 Exercise Training for the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings — 4; 6; 7 Participants
Phase 2 N=51 Geodon for the Treatment of Refractory Social Anxiety Disorder
Social Anxiety Disorder
Primary: Brief Social Phobia Scale(BSPS) — 44.0; 31.8; 31.8; 31.2 units on a scale — p=< 0.001
Phase 4 N=49 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
Bipolar Disorder · Panic Disorder · Generalized Anxiety Disorder
Primary: Clinician Global Improvement Scale (CGI-21) — 7.8; 3.4 units on a scale
Phase 4 N=42 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Social Anxiety Disorder · Social Phobia · Alcohol Use Disorder
Primary: Social Anxiety Severity — 87; 93 units on a scale
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
Phase 4 N=30 Escitalopram in Patients With Social Anxiety Disorder
Social Anxiety Disorder
Primary: Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I) — 2.1 scores on a scale
N/A N=88 Variations of Cognitive Behavior Therapy for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Social Phobia and Anxiety Inventory (SPAI) - Social Phobia Subscale — 131.66; 130.17; 75.47; 103.9 units on a scale
Phase 3 N=370 Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 27.2; 26.0 score…
Phase 3 N=488 Child and Adolescent Anxiety Disorders (CAMS)
Anxiety Disorders · Social Phobia · Generalized Anxiety Disorder
Primary: Clinical Global Impression - Improvement Scale — 54.9; 59.7; 80.7; 23.7 percentage of participants
Phase 4 N=89 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
N/A N=41 Computer-Based Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change in Percent Dwell Time on Threat Faces — 20.7; 27.1 percentage of dwell time on threat faces